Vanguard Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.6M Buy
2,865,304
+168,088
+6% +$631K ﹤0.01% 2721
2026
Q2
$9.9M Buy
2,697,216
+4,268
+0.2% +$26K ﹤0.01% 2826
2026
Q1
$20.7M Buy
+2,692,948
New +$25M ﹤0.01% 2328

Other funds holding FULC

Vanguard Capital Management's FULC Position: Q3 2026 in Review

Vanguard Capital Management increased its Fulcrum Therapeutics (FULC) stake by 6.2% in Q3 2026, buying an estimated $631K and bringing the position to 2,865,304 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2721.

Vanguard Capital Management first reported a position in FULC in Q1 2026 and has held it in 3 quarters since. The position peaked at $20.7M in Q1 2026. 151 funds tracked by Wall St. Rank hold FULC as of Q3 2026.

  • Vanguard Capital Management held 2,865,304 shares of Fulcrum Therapeutics worth $10.6M as of Q3 2026.
  • Vanguard Capital Management bought 168,088 Fulcrum Therapeutics shares in Q3 2026, an estimated $631K.
  • Fulcrum Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2721 holding.
  • Vanguard Capital Management first reported a position in Fulcrum Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Fulcrum Therapeutics position peaked at $20.7M in Q1 2026.
  • 151 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.